Stabilized anti-cancer cold atmospheric plasma (cap)-stimulated media and methods for preparing and using the same

Patent metadata

Field	Value
Publication number	US-2018296830-A1
Application number	US-201615767313-A
Country	US
Kind code	A1
Filing date	Oct 26, 2016
Priority date	Oct 28, 2015
Publication date	Oct 18, 2018
Grant date	—

Abstract

This disclosure relates to stabilized anti-cancer cold atmospheric plasma (CAP)-stimulated media, to methods for preparing such media, and to methods of treatment using such media.

First claim

1 . A stabilized cold atmospheric plasma-stimulated anti-cancer medium,

2 . The medium of claim 1 , wherein the medium comprises phosphate buffered saline (PBS), Dulbecco's Modified Eagle Medium (DMEM), or a combination thereof.

3 . The medium according to claim 1 , wherein the medium comprises phosphate buffered saline (PBS).

4 . The medium according to claim 1 , wherein the medium comprises Dulbecco's Modified Eagle Medium (DMEM).

5 . The medium according to claim 1 , wherein the medium is stable for a period of up to 7 days, up to 6 days, up to 5 days, up to 4 days or up to 3 days.

6 . The medium according to claim 1 , wherein the medium is stable for between about 1 and about 7 days, about 1 and about 6 days, about 1 and about 5 days, about 1 and about 4 days or about 1 and about 3 days.

7 . The medium according to claim 1 , wherein the medium is stable at a temperature of between about −25° C. and about 25° C., between about − 25 ° C. and about 22° C., between about 0° C. and about 22° C., between about 0° C. and about 8° C. or between about 2° C. and about 8° C.

8 . The medium according to claim 1 , wherein the medium is free of cysteine, methionine, or a combination thereof.

9 . The medium according to claim 1 , wherein the medium is free of phenylalanine.

10 . The medium according to claim 1 , wherein the medium is free of phenol red.

11 . The medium according to claim 1 . wherein the medium comprises 3-nitro-L-tyrosine.

12 . The medium according to claim herein the 3-nitro-L-tyrosine is present in the plasma-stimulated media at a concentration of up to 9 mM.

13 . The medium according to claim 11 , wherein the 3-nitro-L-tyrosine is present in the plasma-stimulated media at a concentration of between about 1 and about 5 mM.

14 . The medium according to claim 11 , wherein the 3-nitro-L-tyrosine is present in the plasma-stimulated media at a concentration of about 1 mM, about 2 mM. about 3 MM. or about 4 mM.

15 . A method of stabilizing and/or enhancing the anti-cancer activity of cold atmospheric plasma-stimulated media, the method comprising:
(i) reducing the amount of cysteine, methionine, or a combination thereof, in the media; (ii) reducing the amount of phenylalanine in the media; (iii) reducing the amount of phenol red in the media; (iv) adding 3-nitro-tyrosine to the media; or (v) any combination of (i)-(iv).

16 . A method of treating a target tissue comprising administering to a patient in need of such treatment a medium according to claim 1 .

17 . The method according to claim 16 , wherein the tissue is cancerous tissue.

18 . The method according to claim 16 , wherein the tissue comprises lung tissue, bladder tissue, brain tissue, skin tissue, or any combination thereof.

19 . A method of enhancing the anti-cancer activity of cold atmospheric plasma—
stimulated media, the method comprising;
(i) increasing the diameter of the well in a multi-plate well,
(ii) decreasing the gap between the plasma tube and the surface of the media during the cold atmospheric plasma treatment; or
(iii) any combination of (i) and (ii).

20 . The method according to claim 19 , wherein the diameter of the well is increased by about 42% or about 57%.

21 . The method according to claim 19 , wherein the gap is decreased by about 25%, about 20%, about 17%, or about 14%.

Assignees

• Univ George Washington

Inventors

• Yan Dayun
• Keidar Michael
• Sherman Jonathan

Classifications

• A61M37/00

  Other apparatus for introducing media into the body (for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30); Percutany, i.e. introducing medicines into the body by diffusion through the skin (salt baths A61H33/04) · CPC title

• A61N1/00

  Electrotherapy; Circuits therefor (A61N2/00 takes precedence; irradiation apparatus A61N5/00) · CPC title

• A61B18/042

  using additional gas becoming plasma · CPC title

• H05H2240/20

  Non-thermal plasma · CPC title

• A61N1/36002 Primary

  Cancer treatment, e.g. tumour · CPC title